MedTrace Logo

Bioavailability of Belumosudil (KD025) in Healthy Male Subjects

NCT02557139 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2022-05-25

Study results available
· View outcomes & findings →

Summary

Phase 1 bioavailability study to evaluate the pharmacokinetics (PK) and tolerability/safety of the belumosudil tablet formulation in the fasted and fed states and compared to the belumosudil capsule formulation in the fed state.

Conditions

  • Bioavailability

Interventions

DRUG

Belumosudil Tablet

DRUG

Belumosudil Capsule

Sponsors & Collaborators

  • Quotient Clinical

    collaborator OTHER

  • Kadmon Corporation, LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2015-10-12
Completion
2015-10-12

Countries

  • United Kingdom

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02557139 on ClinicalTrials.gov